Global Anemia Market Report to 2030 – Insight, Epidemiology and Forecasts –

Global Anemia Market Report to 2030 – Insight, Epidemiology and Forecasts –

Global Anemia Market Report to 2030 – Insight, Epidemiology and Forecasts –

DUBLIN–(BUSINESS WIRE)–The “Anemia Market Insight, Epidemiology and Market Forecast 2030” report has been added to’s offering.

This report delivers an in-depth understanding of the IDA, historical and forecasted epidemiology as well as the IDA market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The IDA market report provides emerging drugs, IDA market share of the individual cancer types, current and forecasted IDA market size from 2018 to 2030 segmented by seven major markets. The Report also covers current IDA market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted IDA epidemiology [segmented as Total prevalent cases of IDA, Total diagnosed prevalent cases of IDA, Total IDA cases by gender, Total IDA cases by pathology, Severity specific diagnosed cases of IDA, and Total Treated cases of IDA] scenario of IDA in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.

Country Wise- IDA Epidemiology

  • In 2020, the total prevalent cases of IDA were 30,829,734 in the 7MM. The United States, in the same year, accounted for 9,313,895 cases. According to the analysis, Japan had the highest prevalence of IDA cases in the 7MM, accounting for approximately 39% of the total 7MM cases in 2020.
  • IDA is often underdiagnosed and undertreated, as some people may not have any symptoms at first. In the EU-5 countries, the total diagnosed prevalent cases of IDA were 4,277,646 in 2020. Many programs have been launched in an attempt to minimize the prevalence of IDA in the Western world. Screeni ng, health education, iron fortification of food, and increased usage of iron-rich baby formula are among them.
  • Females are more likely to be afflicted by IDA than men. In 2020, the total IDA cases in women health were estimated around 2,060,787 in the 7MM. Among all the pathology related cause of IDA, IDA in chronic kidney disease have the highest patient pool in 2020.
  • When a patient is diagnosed with IDA, an iron-rich diet and oral iron supplements can help treat the majority of mild-to-moderate IDA cases. In the 7MM, it is accessed that 9,266,923 cases received first-line oral therapies. Some of the patients who have received first-line oral treatments fail and move to second-line oral medications such as Feraccru (Accrufer) and Auryxia (Riona). Moreover, some proportion of patients who receive second-line oral treatments and who have severe IDA will proceed to IV iron therapy.

Scope of the Report

  • The report covers the descriptive overview of IDA, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the IDA epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for IDA is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of IDA market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global IDA market.

Report Highlights

  • In the coming years, IDA market is set to change due to the entry of new oral iron supplements having fewer side effects, an increase in the number of IDA patients mainly due to general lifestyle changes and also due to risk factors like malaria are some of the major factors expected to contribute in the growth of the IDA market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence IDA R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for IDA. Launch of emerging therapies, will significantly impact the IDA market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Companies Mentioned

  • Akebia Therapeutics
  • AMAG Pharmaceuticals
  • American Regent
  • MegaPro Biomedical
  • Nemysis
  • Pharmacosmos Therapeutics
  • Shield Therapeutics
  • Vifor Pharma

For more information about this report visit


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900